Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

January 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab (drug), Herceptin (drug)

Trial Locations (18)

30045

Suburban Hematology-Oncology Associates, P.A., Lawrenceville

30060

Northwest Georgia Oncology Centers, P.C., Marietta

30607

Northeast Georgia Cancer Care, LLC, Athens

32804

Cancer Institute of Florida, P.A., Orlando

61615

Oncology Hematology Associates of Central Illinois, P.C., Peoria

89109

Comprehensive Cancer Centers of Nevada, Las Vegas

90095

UCLA Medical Center, Los Angeles

90277

Cancer Care Associates Medical Group, Inc., Redondo Beach

90813

Pacific Shores Medical Group, Long Beach

91328

North Valley Hematology/Oncology Medical Group, Northridge

91767

Wilshire Oncology Medical Group, Inc., Pomona

91801

Central Hematology Oncology Medical Group, Inc., Alhambra

92081

San Diego Cancer Center, Vista

92835

Virginia K. Crosson Cancer Center, Fullerton

93030

Ventura County Hematology-Oncology Specialists, Oxnard

93105

Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara

Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara

93309

Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Translational Oncology Research International

OTHER